These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 15581967)

  • 1. ERBB-2 gene overexpression and amplification in uterine sarcomas.
    Amant F; Vloeberghs V; Woestenborghs H; Debiec-Rychter M; Verbist L; Moerman P; Vergote I
    Gynecol Oncol; 2004 Dec; 95(3):583-7. PubMed ID: 15581967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uterine sarcomas: a review.
    D'Angelo E; Prat J
    Gynecol Oncol; 2010 Jan; 116(1):131-9. PubMed ID: 19853898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.
    Livasy CA; Reading FC; Moore DT; Boggess JF; Lininger RA
    Gynecol Oncol; 2006 Jan; 100(1):101-6. PubMed ID: 16157366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
    Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
    Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.
    Santin AD; Bellone S; Van Stedum S; Bushen W; De Las Casas LE; Korourian S; Tian E; Roman JJ; Burnett A; Pecorelli S
    Gynecol Oncol; 2005 Jul; 98(1):24-30. PubMed ID: 15894362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma.
    Slomovitz BM; Broaddus RR; Burke TW; Sneige N; Soliman PT; Wu W; Sun CC; Munsell MF; Gershenson DM; Lu KH
    J Clin Oncol; 2004 Aug; 22(15):3126-32. PubMed ID: 15284264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of CD10 in malignant müllerian mixed tumors and adenosarcomas: an immunohistochemical study.
    Mikami Y; Hata S; Kiyokawa T; Manabe T
    Mod Pathol; 2002 Sep; 15(9):923-30. PubMed ID: 12218209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets.
    Cimbaluk D; Rotmensch J; Scudiere J; Gown A; Bitterman P
    Gynecol Oncol; 2007 Apr; 105(1):138-44. PubMed ID: 17175012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system.
    D'Angelo E; Spagnoli LG; Prat J
    Hum Pathol; 2009 Nov; 40(11):1571-85. PubMed ID: 19540555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles.
    Ioffe YJ; Li AJ; Walsh CS; Karlan BY; Leuchter R; Forscher C; Cass I
    Gynecol Oncol; 2009 Dec; 115(3):466-71. PubMed ID: 19767065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors in uterine sarcoma.
    Gadducci A
    Best Pract Res Clin Obstet Gynaecol; 2011 Dec; 25(6):783-95. PubMed ID: 21764643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenosarcoma.
    Amant F; Schurmans K; Steenkiste E; Verbist L; Abeler VM; Tulunay G; De Jonge E; Massuger L; Moerman P; Vergote I
    Gynecol Oncol; 2004 Jun; 93(3):680-5. PubMed ID: 15196864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
    Simonetti S; Russo R; Ciancia G; Altieri V; De Rosa G; Insabato L
    Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?
    Raspollini MR; Susini T; Amunni G; Paglierani M; Taddei A; Marchionni M; Scarselli G; Taddei GL
    Gynecol Oncol; 2005 Jan; 96(1):159-67. PubMed ID: 15589595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER-2/neu oncogene in uterine carcinosarcoma on tamoxifen therapy.
    Raspollini MR; Mecacci F; Paglierani M; Marchionni M; Taddei GL
    Pathol Res Pract; 2005; 201(2):141-4. PubMed ID: 15901136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclooxygenase-2 expression in malignant mesenchymal tumors and related uterine lesions.
    Matsumoto Y; Ishiko O; Sumi T; Yoshida H; Deguchi M; Nakagawa E; Haba T; Wakasa K; Ogita S; Ando Y
    Oncol Rep; 2001; 8(6):1225-7. PubMed ID: 11605037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of Wilms' tumour gene 1 (WT1) in uterine sarcomas.
    Coosemans A; Nik SA; Caluwaerts S; Lambin S; Verbist G; Van Bree R; Schelfhout V; de Jonge E; Dalle I; Jacomen G; Cassiman JJ; Moerman P; Vergote I; Amant F
    Eur J Cancer; 2007 Jul; 43(10):1630-7. PubMed ID: 17531467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland.
    Cornolti G; Ungari M; Morassi ML; Facchetti F; Rossi E; Lombardi D; Nicolai P
    Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1031-6. PubMed ID: 17938328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognoses and prognostic factors of carcinosarcoma, endometrial stromal sarcoma and uterine leiomyosarcoma: a comparison with uterine endometrial adenocarcinoma.
    Akahira J; Tokunaga H; Toyoshima M; Takano T; Nagase S; Yoshinaga K; Tase T; Wada Y; Ito K; Niikura H; Yamada H; Sato A; Sasano H; Yaegashi N
    Oncology; 2006; 71(5-6):333-40. PubMed ID: 17690557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT.
    Rushing RS; Shajahan S; Chendil D; Wilder JL; Pulliam J; Lee EY; Ueland FR; van Nagell JR; Ahmed MM; Lele SM
    Gynecol Oncol; 2003 Oct; 91(1):9-14. PubMed ID: 14529657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.